A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

NCT06042894 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: BL-B01D1
DRUG: SI-B003

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.